Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 150 mg (equivalent: cefuroxime, qty 125 mg) - suspension, powder for - excipient ingredients: aspartame; stearic acid; sucrose; povidone; xanthan gum; acesulfame potassium; flavour - zinnat suspension is indicated for the treatment of the following mild to moderately severe infections caused by sensitive bacteria in paediatric patients aged 3 months to 12 years: tonsillitis and pharyngitis, acute bacterial otitis media. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefuroxime axetil appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime axetil in the subsequent prevention of rheumatic fever are not available at present.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 300 mg (equivalent: cefuroxime, qty 250 mg) - suspension, powder for - excipient ingredients: povidone; sucrose; stearic acid; flavour - zinnat suspension is indicated for the treatment of the following mild to moderately severe infections caused by sensitive bacteria in paediatric patients aged 3 months to 12 years: tonsillitis and pharyngitis, acute bacterial otitis media. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefuroxime axetil appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime axetil in the subsequent prevention of rheumatic fever are not available at present.

Israel - English - Ministry of Health

novartis israel ltd., israel - cefuroxime as axetil - tablets - cefuroxime as axetil 125 mg - cefuroxime - cefuroxime - zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months .• acute streptococcal tonsillitis and pharyngitis.• acute bacterial sinusitis.• acute otitis media.• acute exacerbations of chronic bronchitis.• cystitis.• pyelonephritis.• uncomplicated skin and soft tissue infections. •treatment of early lyme disease.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

novartis israel ltd., israel - cefuroxime as axetil - tablets - cefuroxime as axetil 250 mg - cefuroxime - cefuroxime - zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months .• acute streptococcal tonsillitis and pharyngitis.• acute bacterial sinusitis.• acute otitis media.• acute exacerbations of chronic bronchitis.• cystitis.• pyelonephritis.• uncomplicated skin and soft tissue infections. •treatment of early lyme disease.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

novartis israel ltd., israel - cefuroxime as axetil - tablets - cefuroxime as axetil 500 mg - cefuroxime - zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months .• acute streptococcal tonsillitis and pharyngitis.• acute bacterial sinusitis.• acute otitis media.• acute exacerbations of chronic bronchitis.• cystitis.• pyelonephritis.• uncomplicated skin and soft tissue infections. •treatment of early lyme disease.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 150 mg (equivalent: cefuroxime, qty 125 mg) - suspension, powder for - excipient ingredients: stearic acid; sucrose; povidone; flavour - zinnat suspension is indicated for the treatment of the following mild to moderately severe infections caused by sensitive bacteria in paediatric patients aged 3 months to 12 years: tonsillitis and pharyngitis, acute bacterial otitis media. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefuroxime axetil appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime axetil in the subsequent prevention of rheumatic fever are not available at present.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 300.72 mg (equivalent: cefuroxime, qty 250 mg) - tablet, film coated - excipient ingredients: propylene glycol; microcrystalline cellulose; croscarmellose sodium; hydrogenated vegetable oil; hypromellose; methyl hydroxybenzoate; colloidal anhydrous silica; propyl hydroxybenzoate; sodium lauryl sulfate; titanium dioxide; purified water; sodium benzoate; industrial methylated spirit - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria. . acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. . acute exacerbations of chronic bronchitis, or acute bronchitis. . skin and skin structure infections, for example, furunculosis, pyoderma and impetigo. . acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 150.36 mg (equivalent: cefuroxime, qty 125 mg) - tablet, film coated - excipient ingredients: propylene glycol; sodium lauryl sulfate; croscarmellose sodium; propyl hydroxybenzoate; methyl hydroxybenzoate; hypromellose; microcrystalline cellulose; hydrogenated vegetable oil; colloidal anhydrous silica; titanium dioxide; purified water; sodium benzoate; industrial methylated spirit - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria. . acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. . acute exacerbations of chronic bronchitis, or acute bronchitis. . skin and skin structure infections, for example, furunculosis, pyoderma and impetigo. . acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.